Are AI-driven insights the future of precision medicine, reshaping clinical data analysis as we know it?

The inherent complexity of cancer and the particular requirements for unravelling new biomarkers and predicting treatment response warrants a novel approach that integrates biological, clinical, and all other potentially relevant data sources, with AI.

In the presented case study, myNEO Therapeutics Intelligence’s expertise in big data analysis and immuno-oncology was used to gain more insights into the interplay of immunogenic & molecular responses of HOOKIPA Pharma Inc.‘s lead oncology candidate, HB-200.